Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Aim. To compare the efficacy and safety of carvedilol in men and women with mild to moderate arterial hypertension, associated with obesity and/or compensated diabetes type 2. Material and methods. Hypertensive patients (n=592, 176 men and 416 women) with obesity and/or diabetes were involved into randomized comparative open-label study in parallel groups. Patients were randomized into two groups. Patients of group A (n=291: 90 men and 201 women) kept on to receive previous antihypertensive drugs except beta-blockers which were withdrawn and replaced with carvedilol (Acridilole®, PLC “Akrikhin”, Russia). Patients of control group (n=301: 86 men and 215 women) kept on to receive only previous antihypertensive drugs. Efficacy of antihypertensive therapy was assessed at every 2-week visits during 24-week observation. Biochemical parameters of glucose and lipid metabolism, 12-lead ECG were evaluated at baseline and at the end of the study. Target blood pressure (BP) achievement and safety was assessed in 24 weeks of treatment. Results. Women had more severe metabolic abnormalities compared with men. By the 24th week of treatment significant reduction in systolic BP , diastolic BP , and heart rate was found in the both groups of patients regardless of gender , intergroup differences were significant (p<0,05). By the end of the study target BP level was achieved in 96.3% of men and 96,8% of women in group A and 85.9% and 88.8%, respectively , in the control group (p<0,001). The number of hospital admissions decreased in 4.8 times in men (p<0.0001) and 12 times - in women (p<0.05) in group A, and in 2.7 and 3.3 times, respectively , — in the control group (p<0.0001). Mild to moderate side effects were observed in 32 patients: 19 and 13 patients in group A and control group, respectively (p=0.58). Adverse event rate was not distinguished significantly between men and women. Conclusion: The results show comparable high efficacy and safety of carvedilol in hypertensive men and women with concomitant diseases and high metabolic and cardiovascular risk.

About the Authors

S. A. Shalnova
Russian Cardiology Research and Production Complex
Russian Federation

S. Yu. Martsevich
State Research Center for Preventive Medicine
Russian Federation

A. D. Deev
State Research Center for Preventive Medicine
Russian Federation

Yu. V. Lukina
State Research Center for Preventive Medicine
Russian Federation

E. N. Hoseva
Chemical and pharmaceutical concern “Akrikhin”
Russian Federation


1. Wassertheil-Smoller S., Anderson G., Psaty B.M. et al. Hypertension and its treatment in postmenopausal women: base¬line data from the Women’s Health Initiative. Hypertension 2000;36(5):780-9.

2. Lloyd-Jones D.M., Evans J.C., Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005;294(4):466-72.

3. Westheim A., Klemetsrud T., Tretli S. et al. Blood pres¬sure levels in treated hypertensive patients in general practice in Norway. Blood Press 2001;10(1):37-42.

4. Ong K.L., Tso A.W., Lam K.S., Cheung B.M. Gender differences in BP control and CV risks in Ameri-cans with hypertension. Hypertension 2008; 51(4):1142-8.

5. Shal'nova S.A., Deev A.D., Vikhireva O.V. et al. The prevalence of hypertension in Russia. Awareness, treatment, control. Profilaktika zabolevaniy i ukreplenie zdorov'ya 2001;2:3-7. Russian (Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Распространенность артериальной гипертонии в России. Информированность, лечение, контроль. Профилактика заболеваний и укрепление здоровья 2001;2:3-7).

6. Results of the second stage of monitoring the epidemiological situation of arterial hypertension in Russia (2005 to 2007), conducted under the Federal Target Program «Prevention and treatment of hypertension in the Russian Federation» Information and statistical compilation. Moscow: State Research Center PM; 2008. Russian (Результаты второго этапа мониторинга эпидемиологической ситуации по артериальной гипертонии в РФ (2005-2007гг), проведенного в рамках ФЦП «Профилактика и лечение артериальной гипертонии в Российской Федерации». Информационно-статистический сборник. Москва: ГНИЦ ПМ; 2008).

7. Shal'nova S.A., Deev A.D. Body weight in men and women (results of a survey of a representative sample of the population). Kardiovaskulyarnaya terapiya i profilaktika 2008; 7(6): 60-63. Russian (Шальнова С.А., Деев А.Д. Масса тела у мужчин и женщин (результаты обследования представительной выборки населения). Кардиоваскулярная терапия и профилактика 2008; 7(6): 60-63).

8. Timofeeva T.N., Shal'nova S.A., Konstantinov V.V. i dr. The prevalence of factors influencing the prognosis of patients with arterial hypertension and the assessment of overall cardiovascular risk. Kardiovaskulyarnaya terapiya i profilaktika 2005; 4(6) part I: 15-24. Russian (Тимофеева Т.Н., Шальнова С.А., Константинов В.В. и др. Распространенность факторов, влияющих на прогноз больных артериальной гипертонией и оценка общего сердечно-сосудистого риска. Кардиоваскулярная терапия и профилактика 2005; 4(6) ч.1: 15-24).

9. Oganov R.G., Shal'nova S.A., Deev A.D., i dr. Arterial hypertension and mortality from cardiovascular disease and contribute to life expectancy. Profilaktika zabolevaniy i ukreplenie zdorov'ya 2001; 4: 11-15. Russian (Оганов Р.Г., Шальнова С.А., Деев А.Д., и др. Артериальная гипертония, смертность от сердечно-сосудистых заболеваний и вклад в продолжительность жизни населения. Профилактика заболеваний и укрепление здоровья 2001; 4: 11-15).

10. Dahlof B., Devereux R.B., Kjeldsen S.E. et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311): 995-1003.

11. Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004;363(9426):2022-31.

12. Dahlof B., Sever P.S., Poulter N.R. et al. ASCOT Investigators. Preven¬tion of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Car¬diac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366(9489):895-906.

13. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blockers vs diuretic. The Antihypertensive and Lipid-Lower¬ing Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981-97.

14. Os I., Franco V., Kjeldsen S.E. et al. Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2008;51(4):1103-8.

15. Zanchetti A., Julius S., Kjeldsen S. et al. Outcomes in subgroups of hypertensive patients treat¬ed with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hyper-tens 2006;24(11):2163–8.

16. Wing L.M., Reid C.M., Ryan P. et al Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibi¬tors and diuretics for hypertension in the elderly. New Eng J Med 2003;348(7):583-92.

17. Trenkwalder P., Elmfeldt D., Hofman A. et al. The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients. Blood Press 2005;14(1):31–3.

18. Lewis C.E., Grandits A., Flack J. et al. Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension: results of the Treatment of Mild Hy¬pertension Study. Arch Intern Med 1996;156(4):377-85.

19. Shal'nova S.A., Martsevich S.Iu., Deev A.D. et al. First results of open randomized clinical study of Acridilol in combination therapy of patients with arterial hypertension and obesity or type 2 diabetes (Mellitus-Open Multicenter Clinical Study ACCORD). Kardiologiia 2008;48(8):28-33. Russian (Шальнова С.А., Марцевич С.Ю., Деев А.Д., и др. Первые результаты открытого многоцентрового рандомизированного клинического исследования по применению препарата акридилол в комбинированной терапии у больных артериальной гипертонией и ожирением или сахарным диабетом 2-го типа (АККОРД). Кардиология 2008; 8: 28 – 33).

20. Burt V.L., Cutler J.A., Higgins M., Horan M.J., Labarthe D. et al.: Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the Health Examination Surveys, 1960-1991. Hypertension 1995: 26:60-69.

21. Gudmundsson L.S., Johannsson M., Thorgeirsson G. et al. Hypertension Control as Predictor of Mortality in Treated Men and Women, Followed for up to 30 Years. Cardiovascular Drugs and Therapy 2005; 3:227-235

22. Haffner S.M., Lehto S., Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–234

23. Wexler D.J., Grant R.W., Meigs J.B. et al. Sex Disparities in Treatment of Cardiac Risk Factors in Patients With Type 2 Diabetes. Diabetes Care 2005 28:514–520

24. Gueyffier F., Boutitie F., Boissel J.P. et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997; 126: 761-767.

25. Gel'tser B.I., Kotel'nikov V.N., Volkonskaia O.G. et al. Clinicofunctional evaluation of hypotensive effect of carvedilol in elderly patients with mild and moderate arterial hypertension. Ter Arkh 2001;73(9):13-7. Russian (Гельцеp Б.И., Котельников В.Н., Волконская О.Г. и др. Клинико-функциональная оценка гипотензивного эффекта каpведилола у лиц пожилого возpаста с мягкой и умеpенной аpтеpиальной гипеpтонией. Терапевтический архив 2001;9:13-17).

26. Kobalava Zh.D., Kotovskaya Yu.V., Sokolova M.A. i dr. Effektivnost' i perenosimost' karvedilola pri lechenii srednetyazheloy essentsial'noy gipertonii. Kardiologiia 1998;2:52-56. Russian (Кобалава Ж.Д., Котовская Ю.В., Соколова М.А. и др. Эффективность и переносимость карведилола при лечении среднетяжёлой эссенциальной гипертонии. Кардиология 1998;2:52-56).

27. Yarmukhamedova G.Kh. Efficacy of carvedilol in patients with essential hypertension older. Kardiovaskulyarnaya terapiya i profilaktika 2004; 6(3) part II: 30-33. Russian (Ярмухамедова Г.Х. Эффективность применения карведилола у больных эссенциальной артериальной гипертонией пожилого возраста. Кардиоваскулярная терапия и профилактика 2004; 6(3) часть II: 30-33).

28. Martsevich S.Y., Kutishenko N.P., Shilova E.V. et al. Comparison of therapies based on carvedilol and metoprolol in hypertensive patients with overweight or obesity. The first results of CAMELLIA trial. Rational Pharmacother Card 2009;1:23-27. Russian (Марцевич С.Ю., Кутишенко Н.П., Шилова Е.В. и др. Сравнение терапии, основанной на карведилоле и метопрололе, у больных артериальной гипертонией и избыточной массой тела/ожирением: многоцентровое исследование, направленное на достижение целевого уровня АД при длительной терапии. Рациональная Фармакотерапия в Кардиологии 2009; 5(1):23-27).

29. Chikhladze N.M., Chazova I.E. The possibility of using beta-blockers with vasodilating properties in patients with hypertension. Consilium medicum 2004;2:39–41. Russian (Чихладзе Н.М., Чазова И.Е. Возможности применения бета-адреноблокаторов с вазодилатирующими свойствами у больных с артериальной гипертонией. Consilium medicum 2004;2:39–41).

30. Lyakishev A.A. Sravnenie metabolicheskikh effektov karvedilola i metoprolola u bol'nykh s sakharnym diabetom 2-go tipa i AG. Kardiologiia 2005;4:82-83. Russian (Лякишев А.А. Сравнение метаболических эффектов карведилола и метопролола у больных с сахарным диабетом 2-го типа и АГ. Кардиология 2005;4:82-83).

31. Bakris G.L., Fonseca V., Katholi R.E. et al. Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension. JAMA 2004:292:2227—223.

For citation:


Views: 413

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)